Abstract: The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian glycosylation.

Abstract: The invention relates to a method for the selection of epitopes for immunotherapy, peptides obtained by said method, the use of said peptides as vaccines and diagnostics and an immune serum obtainable by said method.

Abstract: Described is the use of an immunotherapeutic agent targeting a human tumor associated antigen for the production of a medicament for immunotherapy of patients with rectal cancer or being at risk of rectal cancer, wherein the immunotherapeutic agent is a vaccine, an antibody or derivative or fragment thereof.

Abstract: The invention relates to the use of a preparation based on an antibody directed against a tumor-associated antigen, for producing a medicament for the intra-operative treatment of tumor patients, in particular for the prophylactic treatment to prevent the dissemination of tumor cells. The invention further relates to a kit for the intra-operative treatment of tumor patients, comprising the medicament and means for diagnostically determining malignant tumor cells.

Abstract: The use of an antibody directed against the cellular membrane antigen EpCAM for the production of a pharmaceutical preparation for the prophyactic and/or therapeutic active immunization against cancer is provided whereby the antibody is in an amount of 1 ng to 9 ?g.

Abstract: The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations.

Abstract: The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen.

Abstract: Disclosed is the use of a vaccine based on a tumor-associated antigen, its epitope, mimotope, specific or anti-idiotypic antibody, for preparing a medicament for the prophylactic and/or therapeutic active immunization against cancer, in combination with chemotherapy.

Abstract: The invention relates to the use of a polyclonal immunoglobulin preparation for producing a vaccine formulation, containing antibodies of various specific natures for immunising individuals of the same species from which the immunoglobulins are supplied. Said actively immunising preparation can be used, for example, for the prophylaxis or treatment of cancer, auto-immune diseases, allergies and susceptibility to viral, bacterial or fungal infections.

Abstract: The present invention relates to a process for the transcriptionless amplification of nucleic acids or nucleic acid sequences by means of enzymes in which the nucleic acids or sequences are divided at least partially into their individual strands before amplification and/or transcribed and the reaction mixture contains oligonucleotides with a base sequence essentially complementary to those of the ends of the nucleic acids or sequences to be amplified, where said oligonucleotides can, in certain conditions, form starting points and/or chemical components for the synthesis of nucleic acids and are built into the amplification product to be formed. The product of the components itself again corresponds to the nucleic acid or sequence to be amplified. The reaction product formed from the oligonucleotide components, possibly from the templates and other chemical components, reacts again in one step with the oligonucleotide components, the reaction being conducted substantially isothermally.

Abstract: This invention concerns peptides binding to antibodies which show neutralizing activity against different strains and clinical isolates of HIV-1 and which inhibit the fusion of cells infected with HIV-1. These peptides are combined with an adjuvant, as recombinant fusion proteins, chemically coupled to carrier molecules, as recombinant chimeric viruses or as recombinant antibodies.

Abstract: The present invention relates to fusion peptides wherein at least one peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 25 is bound to an adjuvant being a protein molecule by fusion of the respective nucleotide sequences and subsequent expression of the fusion genes in a biological expression system.

Abstract: This invention refers to peptides binding to antibodies that show neutralizing activity against different strains and clinical isolates of HIV-1 and that inhibit the fusion of cells caused by HIV-1. These peptides are applied with an adjuvant, as recombinant fusion proteins, chemically coupled to carrier molecules, as recombinant chimeric viruses or as recombinant antibodies.